Table 3.
Percent change from baseline at 3 and 12 months in clinical characteristics and levels of adipokines and biomarkers of inflammation and oxidative stress from cohort 2 (N = 13)
| 3 months Mean % change (95%CI) |
12 months Mean % change (95%CI) |
Baseline vs. 3 months p-value | Baseline vs. 12 months p-value | |
|---|---|---|---|---|
| Weight (kg) | −21.4% (−19.4 to −23.6%) |
−35.5% (−29.9 to −41.0%) |
p<0.001 | p<0.001 |
| BMI (kg/m2) | −21.2% (−19.2 to −23.5%) |
−35.6% (−30.0 to −41.0%) |
p<0.001 | p<0.001 |
| Glucose (mg/dL) | −11.5% (−5.9 to −17.0%) |
−10.3% (−5.5 to 15.3%) |
p=0.002 | p=0.001 |
| Insulin (μU/mL) | −57.9% (−50.4 to −66.3%) |
−62.5% (−55.6 to 68.8%) |
p=0.004 | p=0.001 |
| HOMA-IR | −62.3% (−54.4 to −71.1%) |
−66.6% (−60.4 to −71.9%) |
p=0.002 | p<0.001 |
| IL-6 (pg/mL) | −54.6% (−118.7 to 9.5%) |
−74.4% (−115.7 to −33.2%) |
p<0.05 | p<0.05 |
| TNF-α (pg/mL) | 40.1% (−59.0 to 139.1%) |
−4.2% (−65.6 to 57.2%) |
p=0.321 | p=0.303 |
| Leptin (ng/mL) | −41.7% (−62.7 to 20.7%) |
−61.9% (−77.7 to 46.2%) |
p<0.01 | p<0.001 |
| MCP-1 (pg/mL) | 26.3% (−34.6 to 87.1%) |
−14.5% (−41.3 to 12.3%) |
p=0.591 | p=0.075 |
| Resistin ng/mL) | −10.4% (−27.9 to 7.1%) |
−6.3% (−24.9 to 12.3%) |
p=0.170 | p=0.257 |
| OxLDL (U/L) | −5.4% (−25.8 to 15.0%) |
−16.5% (−32.9 to 0.1%) |
p=0.366 | p=0.188 |
| Adiponectin (μg/mL) | 116.6% (59.2 to 174.1%) |
194.2% (110.5 to 277.9%) |
p<0.01 | p<0.001 |
Data are presented as mean ± standard deviation. IL-6 = interleukin-6; TNF-α = tumor necrosis factor-alpha; MCP-1 = monocyte chemo-attractant protein-1; OxLDL = oxidized LDL cholesterol